




The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 212% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 422%, being 179% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	157,956
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,292
Liabilities, Non-Current	0
Other Assets	30
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	387
Property and Equipment	240
Research and Development	28,452
Selling, General and Administrative Expense	5,885

Output Variable	Value in 1000 USD
Assets	158,226
Liabilities	3,292
Expenses	34,337
Revenues	387
Stockholders Equity	154,934
Net Income	-33,950
Comprehensive Net Income	-33,950
BaseVar	98,121
ECR before Limited Liability	376%
Economic Capital Ratio	422%